APA (7th ed.) Citation

Bissonnette, R., Luger, T., Thaçi, D., Toth, D., Lacombe, A., Xia, S., . . . Mrowietz, U. (2018). Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). Journal of the European Academy of Dermatology & Venereology, 32(9), 1507. https://doi.org/10.1111/jdv.14878

Chicago Style (17th ed.) Citation

Bissonnette, R., et al. "Secukinumab Demonstrates High Sustained Efficacy and a Favourable Safety Profile in Patients with Moderate‐to‐severe Psoriasis Through 5 years of Treatment (SCULPTURE Extension Study)." Journal of the European Academy of Dermatology & Venereology 32, no. 9 (2018): 1507. https://doi.org/10.1111/jdv.14878.

MLA (9th ed.) Citation

Bissonnette, R., et al. "Secukinumab Demonstrates High Sustained Efficacy and a Favourable Safety Profile in Patients with Moderate‐to‐severe Psoriasis Through 5 years of Treatment (SCULPTURE Extension Study)." Journal of the European Academy of Dermatology & Venereology, vol. 32, no. 9, 2018, p. 1507, https://doi.org/10.1111/jdv.14878.